GEN Exclusives

More »

GEN News Highlights

More »
Sep 13, 2007

Virium Pharmaceuticals Gains Rights to Southern Research Institute’s Oncology Compound

  • Southern Research Institute licensed rights to an oncology candidate to Virium Pharmaceuticals. In exchange, Southern Research will receive cash and stock in Virium and will hold seats on the company’s scientific advisory board and the board of directors.

    SR9025 reportedly has shown activity against certain types of leukemia and autoimmune diseases. It is a third generation, novel nucleoside analog that has completed two Phase I trials.

    “This is the first anticancer compound to be licensed after the completion of early clinical trials and we are eager to see it move through the pipeline,” says John A. Secrist, III, Ph.D., president and CEO of Southern Research.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?